Outcome | Intervention | Control | Risk ratio (95% confidence interval) | Risk difference (95% confidence interval) | |||
---|---|---|---|---|---|---|---|
n/N | Risk (%) | n/N | Risk (%) | ||||
Women 18–21 year | Tested | 507/2453 | 20.6 | 485/7829 | 6.2 | 3.3 (3.0 – 3.7) | 14.5% (12.8 – 16.2) |
Diagnosed | 37/2453 | 1.5 | 63/7829 | 0.8 | 1.9 (1.3 – 2.8) | 0.70% (0.18 – 1.2) | |
Treated | 34/2453 | 1.4 | 58/7829 | 0.7 | 1.9 (1.2 – 2.9) | 0.65% (0.15 – 1.2) | |
Women 22–25 year | Tested | 473/2470 | 19.1 | 358/7687 | 4.7 | 4.1 (3.6 – 4.7) | 14.5% (12.9 – 16.1) |
Diagnosed | 29/2470 | 1.2 | 18/7687 | 0.2 | 5.0 (2.8 – 9.0) | 0.94% (0.50 – 1.4) | |
Treated | 26/2470 | 1.1 | 16/7687 | 0.2 | 5.1 (2.7 – 9.4) | 0.84% (0.43 – 1.3) | |
All women | Tested | 980/4923 | 19.6 | 843/15516 | 2.3 | 3.7 (3.4 – 4.0) | 14.5% (13.3 – 15.6) |
Diagnosed | 66/4923 | 1.3 | 81/15516 | 0.5 | 2.6 (1.9 – 3.5) | 0.82% (0.48 – 1.2) | |
Treated | 60/4923 | 1.2 | 74/15516 | 0.5 | 2.6 (1.8 – 3.6) | 0.74% (0.42 – 1.1) | |
Men 18–21 year | Tested | 322/2552 | 12.6 | 124/8060 | 1.5 | 8.2 (6.7 – 10.0) | 11.1% (9.8 – 12.4) |
Diganosed | 20/2552 | 0.8 | 26/8060 | 0.3 | 2.4 (1.4 – 4.3) | 0.46% (0.10 – 0.82) | |
Treated | 15/2552 | 0.6 | 23/8060 | 0.3 | 2.1 (1.1 – 3.9) | 0.30% (0 – 0.62) | |
Men 22–25 year | Tested | 351/2525 | 13.9 | 105/7942 | 1.3 | 10.5 (8.5 – 13.0) | 12.6% (11.2 – 14.0) |
Diagnosed | 19/2525 | 0.8 | 18/7942 | 0.2 | 3.3 (1.7 – 6.3) | 0.53% (0.17 – 0.88) | |
Treated | 14/2525 | 0.6 | 14/7942 | 0.2 | 3.1 (1.5 – 5.6) | 0.38% (0.07 – 0.68) | |
All men | Tested | 673/5077 | 12.4 | 229/16002 | 1.4 | 9.3 (8.0 – 10.8) | 11.8% (10.9 – 12.8) |
Diagnosed | 39/5077 | 0.8 | 44/16002 | 0.3 | 2.8 (1.8 – 4.3) | 0.49% (0.24 – 0.75) | |
Treated | 29/5077 | 0.6 | 37/16002 | 0.2 | 2.5 (1.5 – 4.0) | 0.34% (0.12 – 0.56) |